CA2158148A1 - Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin - Google Patents

Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin

Info

Publication number: CA2158148A1
Authority: CA; Canada
Prior art keywords: virus; hsv; cells; mutant; disc
Prior art date: 1993-03-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002158148A

Other languages

English (en)

Inventor

Stephen Charles Inglis

Michael Edward Griffith Boursnell

Anthony Charles Minson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Cantab Pharmaceuticals Research Ltd

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-03-19

Filing date

1994-03-21

Publication date

1994-09-29

1993-03-19 Priority claimed from GB939305710A external-priority patent/GB9305710D0/en

1993-12-06 Priority claimed from GB939324964A external-priority patent/GB9324964D0/en

1994-03-21 Application filed by Individual filed Critical Individual

1994-09-29 Publication of CA2158148A1 publication Critical patent/CA2158148A1/fr

Status Abandoned legal-status Critical Current

Links

241000700605 Viruses Species 0.000 title claims abstract description 199
230000002950 deficient Effects 0.000 title claims abstract description 18
230000001177 retroviral effect Effects 0.000 title claims abstract description 14
229960005486 vaccine Drugs 0.000 title abstract description 46
208000015181 infectious disease Diseases 0.000 claims abstract description 63
108090000623 proteins and genes Proteins 0.000 claims abstract description 48
101150055782 gH gene Proteins 0.000 claims abstract description 33
241000700584 Simplexvirus Species 0.000 claims abstract description 32
230000002458 infectious effect Effects 0.000 claims abstract description 30
238000002360 preparation method Methods 0.000 claims abstract description 25
238000004519 manufacturing process Methods 0.000 claims abstract description 24
230000001225 therapeutic effect Effects 0.000 claims abstract description 23
230000003612 virological effect Effects 0.000 claims abstract description 20
241000701074 Human alphaherpesvirus 2 Species 0.000 claims abstract description 19
230000010076 replication Effects 0.000 claims abstract description 16
108091007433 antigens Proteins 0.000 claims abstract description 14
239000003814 drug Substances 0.000 claims abstract description 13
102000003886 Glycoproteins Human genes 0.000 claims abstract description 10
108090000288 Glycoproteins Proteins 0.000 claims abstract description 10
230000007547 defect Effects 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims description 21
230000001717 pathogenic effect Effects 0.000 claims description 12
239000002245 particle Substances 0.000 claims description 10
244000052769 pathogen Species 0.000 claims description 9
206010061978 Genital lesion Diseases 0.000 claims description 5
241001529453 unidentified herpesvirus Species 0.000 claims description 3
241000700588 Human alphaherpesvirus 1 Species 0.000 abstract description 29
230000000069 prophylactic effect Effects 0.000 abstract description 14
230000028993 immune response Effects 0.000 abstract description 11
208000009889 Herpes Simplex Diseases 0.000 abstract description 7
210000004027 cell Anatomy 0.000 description 118
238000002255 vaccination Methods 0.000 description 67
241001465754 Metazoa Species 0.000 description 51
241000699670 Mus sp. Species 0.000 description 24
201000010099 disease Diseases 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
239000012636 effector Substances 0.000 description 24
239000012634 fragment Substances 0.000 description 23
208000024891 symptom Diseases 0.000 description 18
108020004414 DNA Proteins 0.000 description 17
239000013612 plasmid Substances 0.000 description 17
108091034117 Oligonucleotide Proteins 0.000 description 16
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 16
230000005951 type IV hypersensitivity Effects 0.000 description 16
208000027930 type IV hypersensitivity disease Diseases 0.000 description 16
239000013598 vector Substances 0.000 description 16
241000700198 Cavia Species 0.000 description 15
238000002649 immunization Methods 0.000 description 15
230000003902 lesion Effects 0.000 description 15
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 14
239000000203 mixture Substances 0.000 description 14
230000000306 recurrent effect Effects 0.000 description 14
230000004044 response Effects 0.000 description 14
239000002609 medium Substances 0.000 description 13
102000004169 proteins and genes Human genes 0.000 description 13
238000000034 method Methods 0.000 description 12
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 11
230000000694 effects Effects 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
238000003752 polymerase chain reaction Methods 0.000 description 11
230000006798 recombination Effects 0.000 description 10
238000005215 recombination Methods 0.000 description 10
210000003501 vero cell Anatomy 0.000 description 10
206010015150 Erythema Diseases 0.000 description 9
239000006285 cell suspension Substances 0.000 description 9
238000010276 construction Methods 0.000 description 9
210000000624 ear auricle Anatomy 0.000 description 9
231100000321 erythema Toxicity 0.000 description 9
240000001307 Myosotis scorpioides Species 0.000 description 8
239000000427 antigen Substances 0.000 description 8
102000036639 antigens Human genes 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
230000002238 attenuated effect Effects 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 6
238000009472 formulation Methods 0.000 description 6
230000007774 longterm Effects 0.000 description 6
230000003472 neutralizing effect Effects 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
230000009467 reduction Effects 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
238000010561 standard procedure Methods 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
238000011725 BALB/c mouse Methods 0.000 description 5
108010067390 Viral Proteins Proteins 0.000 description 5
239000011543 agarose gel Substances 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
238000012217 deletion Methods 0.000 description 5
230000037430 deletion Effects 0.000 description 5
241000700199 Cavia porcellus Species 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
230000014616 translation Effects 0.000 description 4
210000001215 vagina Anatomy 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 3
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
238000007792 addition Methods 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
230000009089 cytolysis Effects 0.000 description 3
210000005069 ears Anatomy 0.000 description 3
230000001815 facial effect Effects 0.000 description 3
210000000609 ganglia Anatomy 0.000 description 3
239000008188 pellet Substances 0.000 description 3
208000037920 primary disease Diseases 0.000 description 3
229960000380 propiolactone Drugs 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000000472 traumatic effect Effects 0.000 description 3
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
208000030090 Acute Disease Diseases 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
102000053602 DNA Human genes 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108700039887 Essential Genes Proteins 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000032420 Latent Infection Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
230000007969 cellular immunity Effects 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
210000003128 head Anatomy 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229960004857 mitomycin Drugs 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000000047 product Substances 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
229960004854 viral vaccine Drugs 0.000 description 2
SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 1
LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000022555 Genital disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 1
241000700327 Herpes simplex virus (type 1 / strain MP) Species 0.000 description 1
208000029433 Herpesviridae infectious disease Diseases 0.000 description 1
241000282414 Homo sapiens Species 0.000 description 1
241001135569 Human adenovirus 5 Species 0.000 description 1
241000701069 Human herpesvirus 2 strain G Species 0.000 description 1
241000701072 Human herpesvirus 2 strain HG52 Species 0.000 description 1
101150027427 ICP4 gene Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
101100345589 Mus musculus Mical1 gene Proteins 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
208000000474 Poliomyelitis Diseases 0.000 description 1
241000219492 Quercus Species 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010006785 Taq Polymerase Proteins 0.000 description 1
101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
101150105144 UL21 gene Proteins 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000612 antigen-presenting cell Anatomy 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
229940031567 attenuated vaccine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000013592 cell lysate Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
238000013401 experimental design Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
101150118163 h gene Proteins 0.000 description 1
238000011597 hartley guinea pig Methods 0.000 description 1
244000144980 herd Species 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
229940124590 live attenuated vaccine Drugs 0.000 description 1
229940023012 live-attenuated vaccine Drugs 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000034217 membrane fusion Effects 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
231100000255 pathogenic effect Toxicity 0.000 description 1
230000007918 pathogenicity Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
238000013310 pig model Methods 0.000 description 1
239000006187 pill Substances 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Immunology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002158148A 1993-03-19 1994-03-21 Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin Abandoned CA2158148A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB939305710A GB9305710D0 (en)	1993-03-19	1993-03-19	Viral vaccines
GB939324964A GB9324964D0 (en)	1993-12-06	1993-12-06	Viral vaccines
GB9305710.7		1993-12-06
GB9324964.7		1993-12-06

Publications (1)

Publication Number	Publication Date
CA2158148A1 true CA2158148A1 (fr)	1994-09-29

Family

ID=26302619

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002158148A Abandoned CA2158148A1 (fr)	1993-03-19	1994-03-21	Virus defectif mutant non retroviral (par ex. hsv), utilise comme vaccin

Country Status (5)

Country	Link
EP (1)	EP0689603A1 (fr)
JP (1)	JPH08507784A (fr)
AU (1)	AU696336B2 (fr)
CA (1)	CA2158148A1 (fr)
WO (1)	WO1994021807A2 (fr)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7223411B1 (en) *	1992-07-31	2007-05-29	Dana-Farber Cancer Institute	Herpesvirus replication defective mutants
US6156319A (en)	1994-07-25	2000-12-05	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex vaccine
US5807557A (en) *	1994-07-25	1998-09-15	The Trustees Of The University Of Pennsylvania	Soluble herpesvirus glycoprotein complex
GB9423663D0 (en) *	1994-11-23	1995-01-11	Cantab Pharma Res	Viral preparations, immunogens, and vaccines
ATE324435T1 (de) *	1995-02-21	2006-05-15	Cantab Pharmaceuticals Res Ltd	Virale zubereitungen, vektoren, immunogene und impfstoffe
AU711702B2 (en) *	1995-03-23	1999-10-21	Cambridge University Technical Services Limited	Vectors for gene delivery
EP0830368A1 (fr)	1995-06-07	1998-03-25	Genta Incorporated	Nouveaux lipides cationiques a base de carbamate
US5851826A (en) *	1995-07-26	1998-12-22	Children's Medical Center Corporation	Helper virus-free herpesvirus vector packaging system
CA2234877A1 (fr) *	1995-10-19	1997-04-24	St. Jude Children's Research Hospital	Vecteurs du virus herpetique et leurs utilisations
US6093816A (en)	1996-06-27	2000-07-25	Isis Pharmaceuticals, Inc.	Cationic lipids
IL132323A0 (en)	1997-04-28	2001-03-19	Rhone Poulenc Rorer Sa	Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
GB9721909D0 (en) *	1997-10-17	1997-12-17	Cantab Pharma Res	Gene delivery vectors and their uses
US6875606B1 (en)	1997-10-23	2005-04-05	The United States Of America As Represented By The Department Of Veterans Affairs	Human α-7 nicotinic receptor promoter
GB9804632D0 (en)	1998-03-05	1998-04-29	Cantab Pharma Res	Virus preparations and methods
GB9808922D0 (en)	1998-04-24	1998-06-24	Cantab Pharmaceuticals Res Ltd	Virus preparations
US6225456B1 (en)	1998-05-07	2001-05-01	University Technololy Corporation	Ras suppressor SUR-5
US6506889B1 (en)	1998-05-19	2003-01-14	University Technology Corporation	Ras suppressor SUR-8 and related compositions and methods
US6399354B1 (en)	1998-07-31	2002-06-04	President And Fellows Of Harvard College	Replication-competent virus expressing a detectable fusion protein
GB9816761D0 (en)	1998-07-31	1998-09-30	Phogen Limited	Herpesvirus preparations and their uses
US6441156B1 (en)	1998-12-30	2002-08-27	The United States Of America As Represented By The Department Of Health And Human Services	Calcium channel compositions and methods of use thereof
GB0018307D0 (en)	2000-07-26	2000-09-13	Aventis Pharm Prod Inc	Polypeptides
CA2399940A1 (fr)	2000-04-13	2001-10-25	The Rockefeller University	Amelioration des reponses immunitaires associees aux anticorps
CA2901451C (fr)	2000-05-10	2020-04-07	Moses Rodriguez	Anticorps igm humains permettant de declencher la remyelinisation, et utilisations de ceux-ci a des fins diagnostiques et therapeutiques, plus particulierement dans le systeme nerveux central
EP1317564B1 (fr)	2000-09-14	2007-08-01	Mount Sinai School of Medicine	Procedes de criblage permettant d'identifier des proteines g et d'autres composes qui modulent l'activite de la phosphodiesterase (pde)
US7060442B2 (en)	2000-10-30	2006-06-13	Regents Of The University Of Michigan	Modulators on Nod2 signaling
ES2359625T3 (es)	2000-12-28	2011-05-25	Wyeth Llc	Proteina protectora recombinante de.
ATE448793T1 (de)	2001-03-02	2009-12-15	Univ Rockefeller	Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
US7803982B2 (en)	2001-04-20	2010-09-28	The Mount Sinai School Of Medicine Of New York University	T1R3 transgenic animals, cells and related methods
MX339524B (es)	2001-10-11	2016-05-30	Wyeth Corp	Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en)	2002-08-30	2010-08-31	Wyeth Holdings Corporation	Immunogenic compositions for the prevention and treatment of meningococcal disease
US7432057B2 (en)	2004-01-30	2008-10-07	Michigan State University	Genetic test for PSE-susceptible turkeys
US7604798B2 (en)	2004-07-15	2009-10-20	Northwestern University	Methods and compositions for importing nucleic acids into cell nuclei
JP4772045B2 (ja)	2004-07-16	2011-09-14	アメリカ合衆国	Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
GB2421025A (en) *	2004-12-09	2006-06-14	Oxxon Therapeutics Ltd	HSV vaccination vectors
US7439327B2 (en)	2005-01-18	2008-10-21	Nuvelo, Inc.	Stem cell factor-like proteins and uses thereof
WO2007005898A2 (fr)	2005-07-05	2007-01-11	Cornell Research Foundation, Inc.	Blocage de l'emigration des leucocytes et de l'inflammation par le blocage de cd99l2
AR064642A1 (es)	2006-12-22	2009-04-15	Wyeth Corp	Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8093043B2 (en)	2008-06-04	2012-01-10	New York University	β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
CA2728739C (fr)	2008-06-20	2017-07-11	Duke University	Utlisation d'antigenes du cytomegalovirus humain pour ameliorer les reponses immunitaires aux cellules cancereuses
WO2009155484A2 (fr)	2008-06-20	2009-12-23	Wyeth	Compositions et procédés d'utilisation d'orf1358 provenant de souches de streptocoques bêta-hémolytiques
BRPI0921286B8 (pt)	2008-11-05	2022-10-25	Wyeth Llc	Composição imunogênica com múltiplos componentes para a prevenção de doença por estreptococos beta-hemolíticos (bhs).
WO2010096561A1 (fr)	2009-02-18	2010-08-26	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Protéines gag du vih/vis de synthèse et leurs utilisations
CA2793521A1 (fr)	2010-03-19	2011-09-22	University Of South Alabama	Utilisation de gli1 antisens afin de reduire la dose d'un compose therapeutique pour traiter un cancer a traiter
KR101594228B1 (ko)	2010-08-23	2016-02-15	와이어쓰 엘엘씨	네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en)	2010-09-10	2014-11-28	Wyeth Llc	Non-lipidated variants of neisseria meningitidis orf2086 antigens
WO2012135696A2 (fr)	2011-04-01	2012-10-04	University Of South Alabama	Procédés et compositions pour le diagnostic, la classification et le traitement du cancer
WO2013103401A1 (fr)	2012-01-06	2013-07-11	University Of South Alabama	Procédés et compositions pour le traitement du cancer
SA115360586B1 (ar)	2012-03-09	2017-04-12	فايزر انك	تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es)	2012-03-09	2018-09-19	Pfizer	Composiciones de neisseria meningitidis y metodos de las mismas.
US9802987B2 (en)	2013-03-08	2017-10-31	Pfizer Inc.	Immunogenic fusion polypeptides
US10981961B2 (en)	2013-03-11	2021-04-20	University Of Florida Research Foundation, Incorporated	Delivery of card protein as therapy for occular inflammation
RU2662968C2 (ru)	2013-09-08	2018-07-31	Пфайзер Инк.	Иммуногенная композиция против neisseria meningitidis (варианты)
EP3049092A4 (fr)	2013-09-24	2017-09-06	Duke University	Compositions, procédés et kits pour déclencher une réponse immunitaire
WO2015127094A1 (fr)	2014-02-19	2015-08-27	University Of Florida Research Foundation, Inc.	Administration de nrf2 en tant que thérapie de protection contre les dérivés réactifs de l'oxygène
US10918712B2 (en)	2014-03-03	2021-02-16	Albert Einstein College Of Medicine	Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
WO2015134368A2 (fr) *	2014-03-03	2015-09-11	Albert Einstein College Of Medicine Of Yeshiva University	Vecteurs de vaccin du virus de l'herpès simplex 2 (vhs -2) de recombinaison(hsv -2)
AU2016221318B2 (en)	2015-02-19	2020-06-25	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
AU2018215585B2 (en)	2017-01-31	2022-03-17	Pfizer Inc.	Neisseria meningitidis compositions and methods thereof
KR102658198B1 (ko)	2017-05-15	2024-04-16	얀센 백신스 앤드 프리벤션 비.브이.	안정한 바이러스 함유 조성물
CN110603058A (zh)	2017-05-15	2019-12-20	扬森疫苗与预防公司	含有病毒的稳定组合物
EP4034157A1 (fr)	2019-09-27	2022-08-03	Pfizer Inc.	Compositions de neisseria meningitidis et méthodes associées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992005263A1 (fr) *	1990-09-25	1992-04-02	Cantab Pharmaceuticals Research Limited	Vaccin viral mutant a genome deficient et produit en transcomplementant la lignee cellulaire
TW289731B (fr) *	1992-07-09	1996-11-01	Akzo Nv
AU4560693A (en) *	1992-07-30	1994-03-03	Akzo Nobel N.V.	Non-shedding live herpesvirus vaccine

1994
- 1994-03-21 EP EP94909990A patent/EP0689603A1/fr not_active Withdrawn
- 1994-03-21 CA CA002158148A patent/CA2158148A1/fr not_active Abandoned
- 1994-03-21 WO PCT/GB1994/000572 patent/WO1994021807A2/fr not_active Ceased
- 1994-03-21 AU AU62617/94A patent/AU696336B2/en not_active Ceased
- 1994-03-21 JP JP6520817A patent/JPH08507784A/ja active Pending

Also Published As

Publication number	Publication date
AU696336B2 (en)	1998-09-10
WO1994021807A2 (fr)	1994-09-29
EP0689603A1 (fr)	1996-01-03
WO1994021807A3 (fr)	1994-12-08
AU6261794A (en)	1994-10-11
JPH08507784A (ja)	1996-08-20

Legal Events

Date	Code	Title	Description
2002-03-21	FZDE	Discontinued

Publication	Publication Date	Title
AU696336B2 (en)	1998-09-10	Defective mutant non-retroviral virus (e.g. HSV) as vaccine
Morrison et al.	1994	Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection
Boursnell et al.	1997	A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
US8501194B2 (en)	2013-08-06	Vaccine for viruses that cause persistent or latent infections
US6541009B1 (en)	2003-04-01	Viral vaccines
Riviere et al.	1992	Protection of mice and swine from pseudorabies virus conferred by vaccinia virus-based recombinants
US5665362A (en)	1997-09-09	Viral vaccines
Spector et al.	1998	Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs
JP5845191B2 (ja)	2016-01-20	単純ヘルペスウイルスワクチン
JP2004535798A (ja)	2004-12-02	ヘルペスウイルスを用いた癌処置のための組成物および方法
Berman et al.	1988	Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs
US5837261A (en)	1998-11-17	Viral vaccines
Baghian et al.	2002	Protective immunity against lethal HSV-1 challenge in mice by nucleic acid-based immunisation with herpes simplex virus type-1 genes specifying glycoproteins gB and gD
AU758604B2 (en)	2003-03-27	Attenuated equine herpesvirus
Zhang et al.	1998	Protective immunity against equine herpesvirus type-1 (EHV-1) infection in mice induced by recombinant EHV-1 gD
US7223411B1 (en)	2007-05-29	Herpesvirus replication defective mutants
Erturk et al.	1992	Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine
AU708460B2 (en)	1999-08-05	A polynucleotide herpes virus vaccine
US7374768B1 (en)	2008-05-20	Viral vaccines
US20020009462A1 (en)	2002-01-24	Herpesvirus replication defective mutants
Lowry et al.	1997	The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1
Skinner et al.	1982	Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFU1 (S-) MRC against primary type 2 herpes simplex virus infection
Koelle et al.	2016	Herpes Simplex Vaccines
Batra	1987	Herpes Simplex Virus Latency: Analysis of Viral Genes Controlling Reactivation
Zhu	1997	Mucosal vaccination against herpesviral infection